Abstract
Arrowhead Pharmaceuticals is scheduled to release its fiscal second-quarter 2026 financial results on May 7, 2026 Post Market; investors will look for clarity on the sustainability of collaboration-driven revenue, operating expense trajectory, and the path of earnings following a milestone-heavy prior quarter.Market Forecast
Consensus tracking for the current fiscal quarter points to revenue of 75.69 million US dollars, an estimated year-over-year increase of 153.09%, with an adjusted EPS forecast of approximately -1.19 and EBIT projected at -177.37 million US dollars; margin forecasts were not provided, so gross and net profit margin outlooks are omitted. The company’s revenue mix is expected to remain skewed toward collaboration and milestone recognition, with any incremental product or royalty contributions likely small relative to collaboration inflows this quarter. The most promising growth contribution remains collaboration programs, led by the company’s largest recent agreement, though segment-level year-over-year comparisons were not disclosed; the most recent revenue breakdown shows 696.80 million US dollars from the Sarepta collaboration, 130.00 million US dollars from Sanofi, and 2.65 million US dollars from global service providers.Last Quarter Review
In fiscal first-quarter 2026, Arrowhead Pharmaceuticals reported revenue of 264.03 million US dollars, a gross profit margin of 100.00%, GAAP net profit attributable to shareholders of 30.81 million US dollars, a net profit margin of 11.67%, and adjusted EPS of 0.22, with year-over-year revenue growth of 10,461.32% and adjusted EPS growth of 115.83%. Net profit rose sequentially by 229.73% as the company recognized sizable collaboration-related revenue, producing a rare combination of triple-digit revenue expansion and positive net income. Main business highlights were concentrated in collaboration economics: the Sarepta collaboration accounted for 696.80 million US dollars, Sanofi contributed 130.00 million US dollars, and global service providers added 2.65 million US dollars, while total revenue for the quarter increased 10,461.32% year-over-year.Current Quarter Outlook
Main revenue drivers and sustainability
The current-quarter revenue estimate of 75.69 million US dollars implies a sharp step-down from the prior quarter’s milestone-rich peak, even as the year-over-year comparison remains favorable at 153.09%. The primary driver remains collaboration revenue recognition, which can vary significantly depending on development and regulatory milestones that fall within the reporting period. Because the previous quarter delivered 100.00% gross margin on a milestone-heavy mix, even a modest change in mix this quarter could translate into pronounced changes in EBIT and EPS. The modeled EBIT loss of 177.37 million US dollars and a forecast adjusted EPS of around -1.19 suggest that operating expenses and investment behind the commercial transition and pipeline are expected to outweigh recognized revenue. Investors should be prepared for volatility in quarterly revenue timing, as collaboration frameworks often yield non-linear recognition schedules that can swing profitability metrics even in the absence of material changes in underlying project momentum.The company’s recent performance underscores how collaboration mechanics can drive financial results within a single quarter. When collaboration and milestone triggers line up, revenue scales rapidly and margins expand because payments typically carry minimal cost of goods, as seen with the 100.00% gross margin last quarter. Conversely, the forecasted EBIT loss indicates an expected normalization in recognized collaboration revenue this period alongside continued operating expenditures. Within this dynamic, the “headline” revenue line is the key swing factor for short-term earnings power, while expense levels are likely to remain elevated and relatively stable as programs advance. As a result, the near-term earnings path will pivot on the cadence of collaboration events rather than broad-based product revenues.
Most promising business and incremental growth catalysts
Collaboration programs remain the most promising near-term growth engine by contribution scale, led most recently by the Sarepta collaboration, which accounted for 696.80 million US dollars in the last reported revenue breakdown. Management’s ongoing execution across partnered programs can provide incremental catalysts in the form of development progress, regulatory milestones, and potential sales-related triggers that may convert into recognized revenue. While segment-level year-over-year growth rates for individual collaborations were not disclosed, the scale of the Sarepta and Sanofi contributions positions collaboration economics as the likely fulcrum for near-term upside surprises. If additional milestones or license fees are achieved during the quarter, revenue could exceed the 75.69 million US dollars estimate, with limited immediate impact on cost of goods sold—supporting potential margin outperformance relative to forecasted operating losses.Beyond collaborations, the early-stage commercial transition has the potential to provide medium-term revenue layering. That said, the current-quarter forecast embeds only modest expectations for new product or royalty streams relative to collaboration inflows. Investors should watch for qualitative updates on commercial uptake and guidance signals that could reshape expectations for the back half of the fiscal year. In the interim, the collaboration backlog and milestone calendar remain the most tangible levers for quarterly revenue outperformance.
Stock price sensitivity and what will move the shares
Share performance this quarter will likely be most sensitive to three financial checkpoints: the presence or absence of additional collaboration revenue recognition, the trajectory of operating expenses relative to guidance, and the magnitude of EPS deviation versus the -1.19 forecast. If collaboration revenue lands closer to the prior quarter’s elevated run-rate rather than the 75.69 million US dollars estimate, even partial upside could materially compress the forecast EBIT loss, with disproportionate benefit to adjusted EPS. Conversely, an in-line or lighter collaboration figure could leave the reported loss profile near consensus ranges or worse, keeping the stock keyed to forward catalysts rather than the print.Margins and expense levels will be closely parsed. Last quarter’s 100.00% gross margin highlights how mix-heavy collaboration revenue can inflate headline profitability, but this margin is unlikely to be repeated if the mix shifts or if other revenue types increase. Investors will focus on whether operating expenses are tracking with the company’s commercial buildout and portfolio advancement, as deviations here may either absorb collaboration upside or exacerbate losses in a quieter milestone quarter. Management’s tone on the visibility of upcoming collaboration events and any commentary on royalty trajectories will shape how investors model second-half fiscal 2026, which, in turn, will influence how much the market rewards or discounts the near-term EPS miss implied by the current forecast.
Analyst Opinions
Bullish commentary dominates in the January 1, 2026 to April 30, 2026 window, with a ratio of bullish to bearish views at 3:0. H.C. Wainwright reiterated a Buy rating, underscoring confidence in the company’s collaboration economics and the potential for continued milestone-driven revenue. Piper Sandler communicated a constructive stance with an aggressive price target, reflecting expectations that the transition from single-quarter spikes to a broader earnings foundation can draw investor interest as execution milestones accrue. Morgan Stanley upgraded the shares to Overweight during the period and lifted its price target to 100 US dollars, highlighting a more favorable risk-reward profile as the company progresses through pivotal development and commercial inflection points.The majority view emphasizes that collaboration structures provide tangible, near-term revenue opportunities that may not require proportional increases in cost of goods sold, preserving the potential for strong incremental margins when milestones are recognized. Analysts also point to the revenue normalization embedded in the current consensus—75.69 million US dollars for the quarter and -1.19 adjusted EPS—as a conservative base that leaves room for upside if even one or two meaningful collaboration events come through before quarter end. The upgrade to Overweight argues that the market may be underappreciating the cadence of upcoming program decisions and regulatory steps that could translate to additional revenue triggers within the next few quarters.
From a qualitative perspective, the bullish camp focuses on three elements: the scale and visibility of partnered pipelines, the operational execution required to convert pipeline progress into financial milestones, and the supportive setup created by a conservative near-term forecast. These institutions note that last quarter’s 10,461.32% year-over-year revenue growth and 229.73% sequential net profit expansion demonstrate leverage when collaboration inflows align with reporting periods. While no analyst contends that such magnitude is sustainable each quarter, the base case assumes that collaboration cash flows and milestone schedules will continue to provide periodic boosts to revenue and adjusted EPS as programs advance. The path to a more balanced, recurring revenue mix remains a medium-term narrative, but the consensus holds that the company has multiple shots on goal that can drive financial outperformance relative to the present quarter’s modeled loss profile.
Analysts also acknowledge that the forecasted EBIT loss of 177.37 million US dollars is consistent with a quarter lacking major milestone recognition and with ongoing investment to support commercial, medical affairs, and late-stage development. The bullish view is that such a loss trajectory is neither unexpected nor structurally problematic given the operating model, particularly if management indicates that upcoming periods include credible, dated milestones. A more optimistic case emerges if management provides better-than-expected visibility on collaboration receipts or if the company indicates that royalty-bearing revenue lines are starting to build, even if modest at first.
In sum, the dominant institutional perspective frames the quarter as a potential reset from an unusually strong base, with manageable near-term losses and clear optionality for upside. Milestone timing remains the swing factor, yet the breadth of partner activity and supportive analyst positioning argue for patience through quarterly variability. If the delivered revenue lands above the 75.69 million US dollars estimate or if management points to near-term triggers that credibly lift second-half expectations, the prevailing Buy and Overweight stances anticipate a constructive share reaction despite a negative EPS print. Conversely, if revenue aligns with or falls below consensus, the bullish cohort expects investors to look through the quarter, anchoring on the pace and quality of upcoming catalysts that could reignite collaboration-driven operating leverage.
Comments